Nivolumab Plus Relatlimab or Ipilimumab in Metastatic Melanoma Stratified by MHC-II Expression
Phase 2
Terminated
- Conditions
- Interventions
- First Posted Date
- 2018-10-30
- Last Posted Date
- 2021-04-20
- Lead Sponsor
- Elizabeth Davis
- Target Recruit Count
- 2
- Registration Number
- NCT03724968
- Locations
- 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
© Copyright 2024. All Rights Reserved by MedPath